New concepts of clinical trials in rheumatoid arthritis
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Rheumatology
Reference13 articles.
1. Can we improve the performance and reporting of investigator-initiated clinical trials Rheumatoid arthritis as an example.;Landewe;Ann Rheum Dis,2014
2. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study).;Burmester;Ann Rheum Dis,2014
3. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy.;Taylor;Ann Rheum Dis,2015
4. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a noninferiority randomised controlled trial.;Mariette;Ann Rheum Dis,2014
5. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, noninferiority trial.;van Herwaarden;BMJ,2015
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis;Annals of the Rheumatic Diseases;2023-01-10
2. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial;The Lancet Rheumatology;2023-01
3. Evolution of clinical trials for rheumatoid arthritis and spondyloarthritis;Current Opinion in Rheumatology;2018-07
4. bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search;Rheumatology and Therapy;2017-03-02
5. The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis;BioMed Research International;2016
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3